Frovatriptan and rizatriptan economic EVAluation: the FREEVA study

Area of Science:

• Pharmacoeconomics
• Migraine Treatment
• Triptan Therapy

Background:

• Compares direct and indirect costs of frovatriptan versus rizatriptan for acute migraine.
• Utilizes data from a randomized, double-blind, cross-over patient preference study.
• Includes drug acquisition, rescue medication, and workplace absenteeism costs.

Purpose of the Study:

• To evaluate the cost-effectiveness of frovatriptan compared to rizatriptan.
• To analyze direct medical costs and indirect costs associated with migraine treatment.
• To inform clinical selection of migraine therapies based on economic factors.

Main Methods:

• Pharmacoeconomic analysis of a multicenter, randomized, double-blind, cross-over study.
• Calculated direct costs: triptan and rescue medication consumption, drug prices.
• Calculated indirect costs: lost work hours due to migraine attacks.

Main Results:

• Frovatriptan required fewer doses per attack than rizatriptan.
• Direct cost per attack was significantly lower for frovatriptan (€9.12) vs. rizatriptan (€13.54).
• Indirect costs were significantly lower for frovatriptan (1.5 lost hours, €24.55) vs. rizatriptan (2.8 lost hours, €45.84).

Conclusions:

• Frovatriptan demonstrated significantly greater cost-effectiveness than rizatriptan.
• Lower acquisition cost, reduced dosage needs, and fewer lost work hours contribute to frovatriptan's economic advantage.
• Findings support considering cost-effectiveness in selecting oral treatments for acute migraine.